INFLAmmasomes NLRP3 in Platelets and Leukocytes During SEPSIS in Intensive Care Unit (INFLA-SEPSIS)

Toulouse University Hospital

Status: Completed

Conditions: Sepsis

Treatments: Other: Blood collection

Study type: Observational

Funder types: Other

Identifiers

NCT04635878

RC31/20/0026

2020-A00593-36 (Other Identifier)

Details and patient eligibility

About

septic shock is the first cause of mortality in intensive care unit. Innate immunity is the body's first line of defense against pathogens

Full description

since their discovery, inflammasomes have an important role during inflammatory response following an aggression. There are intracytoplasmic multiprotein complex activated by cellular stress or infections and is responsible for the release of pro-inflammatory cytokines, including IL-1β. One study focused on the role of the NLRP3 inflammasome in monocyte during sepsis has shown its early alteration that is correlated with mortality. Most studies have analysed inflammasomes in nucleated cells, nevertheless, little is known about inflammasomes in platelets. The aim of the study is to analyze the activation of NLRP3 inflammasome in platelets and leukocytes during sepsis, from patients hospitalized in intensive care unit compare to a control group, until its resolution to better understand the pathophysiology of sepsis

Enrollment: 11 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

SEPSIS GROUP:

Inclusion Criteria:

• hospitalized in intensive care unit with central catheter
• age > or = 18 years
• patients suffering from sepsis
• hospitalized from less than72 hours

Exclusion Criteria:

• patients with curatorship or guardianship
• pregnant women
• patients suffering from malignant blood disease
• patients suffering from disease associated with NLRP3 inflammasome activation

CONTROL GROUP:

Inclusion Criteria:

• hospitalized in intensive care unit with central catheter for other reason than infection
• age > or = 18 years

Exclusion Criteria:

• patients with infection disease
• patients with curatorship or guardianship
• pregnant women
• patients suffering from malignant blood disease
• patients suffering from disease associated with NLRP3 inflammasome activation

Trial design

11 participants in 2 patient groups

Sepsis group

Description:

patients suffering from sepsis hospitalized in intensive care unit

Treatment:

Other: Blood collection

Control group

Description:

patients without infection hospitalized in intensive care unit

Treatment:

Other: Blood collection